Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988080 | 0.93 | NAMPT (0.36) | PPARACHRM4EPHX2NR1H4SCD | |
| SCHEMBL4864969 | 0.93 | SCD (0.42) | PPARAPPARDCHRM4EPHX2NR1H4 | |
| SCHEMBL4988574 | 0.90 | AOC3 (0.43) | PPARACHRM4EPHX2NR1H4SCD | |
| SCHEMBL4990336 | 0.89 | SCD (0.38) | PPARAPPARGPPARDSCD | |
| SCHEMBL4991267 | 0.88 | PPARA (0.42) | PPARASCD | |
| SCHEMBL4986164 | 0.88 | AOC3 (0.35) | PPARA | |
| SCHEMBL4985031 | 0.87 | ALDH1A1 (0.42) | CHRM4SCD | |
| SCHEMBL4871391 | 0.87 | AOC3 (0.39) | — | |
| SCHEMBL4990577 | 0.86 | SCD (0.38) | SCD | |
| SCHEMBL4986021 | 0.86 | AOC3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | PPARA 2346/4885PPARG 2414/4885PPARD 2704/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | PPARA 664/4885PPARG 867/4885PPARD 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.